Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 5, 2003, Pages 820-830

  Bouchain, Giliane ^a   Leit, Silvana ^a   Frechette, Sylvie ^a   Abou Khalil, Elie ^a   Lavoie, Rico ^a,b   Moradei, Oscar ^a   Woo, Soon Hyung ^a   Fournel, Marielle ^a   Yan, Pu T ^a   Kalita, Ann ^a   Trachy Bourget, Marie Claude ^a   Beaulieu, Carole ^a   Li, Zuomei ^a   Robert, Marie France ^a   MacLeod, A Robert ^a   Besterman, Jeffrey M ^a   Delorme, Daniel ^a  

^a METHYLGENE INC   (Canada)

^b BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; SULFONAMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0037468554     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020377a     Document Type: Article

References (32)

1. Hassig, C. A.; Schreiber, S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr. Opin. Chem. Biol. 1997, 1, 300-308.
2. (a) Kouzarides, T. Histone acetylases and deacetylases in cell proliferation. Curr. Opin. Genet. Dev. 1999, 9, 40-48.
3. Strahl, B. D.; Allis, C. D. Nature 2000, 403, 41.
4. (a) Liu, R. J.; Nagy, L.; Inoue, S.; Shao, W.; Miller, W. H.; Evans, R. M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998, 391, 811-814.
5. Meinke, P. T.; Liberator, P. Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Curr. Med. Chem. 2000, 8, 211-235.
6. Saunders, N.; Dicker, A.; Popa, C.; Jones, S.; Dahler, A. Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res. 2000, 59, 399-404.
7. Saunders, N.; Popa, C.; Serewko, M. M.; Jones, S.; Dicker, A. J.; Dahler, A. L. Histone deacetylase inhibitors: novel anticancer agents. Exp. Opin. Invest. Drugs. 1999, 8, 1611-1621.
8. (a) Beppu, T.; Suginami-ku, H.; Iwamoto, Yoshida, M. U.S. Patent 4,690,918, 1987.
9. Yoshida, M.; Kijima, M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 1990, 265, 17174-17179.
10. Fleming, I.; Iqbal, J.; Krebs, E. P. The total synthesis of (±)-Trichostatin A. Tetrahedron 1983, 39, 841-846.
11. Mori, K.; Koseki, K. Synthesis of Trichostatin A, a potent differentiation inducer of friend leukemic cells, and its antipode. Tetrahedron 1988, 44, 6013-6020.
12. (a) Richon, V. M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind, R. A.; Marks, P. A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 3003-3007.
13. Butler, L. M.; Agus, D. B.; Scher, H. I.; Higgins, B.; Rose, A.; Cordon-Cardo, C.; Thaler, H. T.; Rifkind, R. A.; Marks, P.; Richon, V. M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 2000, 60, 5165-5170.
14. Huang, L.; Pardee, A. B. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol. Med. 2000, 6, 849-866.
15. (a) Remiszewski, S. W.; Sambucetti, L. C.; Atadja, P.; Bair, K. W.; Cornell, W. D.; Green, M. A.; Howell, K. L.; Jung, M.; Kwon, P.; Trogani, N.; Walker H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 2002, 4, 753-757.
16. Jung, M.; Brosch, G.; Kölle, D.; Scherf, H.; Gerhäaser, C.; Loidl, P. Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 1999, 42, 4669-4679.
17. (a) Kim, Y. B.; Lee, K. H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oncogene 1999, 18, 2461.
18. (b) Ohtani, M.; Takaharu, M.; Kazuhiro, S.; Kenji, S. (2E)-5-[3-[(Phenylsulfonyl)-amino]phenyl]-pent-2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation. J. Med. Chem. 1996, 39, 2871-2873.
19. (a) Suzuki, T.; Ando, T.; Tsuchiya, K.; Fukazawa, N.; Saito, A.; Mariko, Y.; Yamashita, T.; Nakanishi, O. Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J. Med. Chem. 1999, 42, 3001-3003.
20. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T.; Suzuki, T.; Tsuruo, T.; Nakanishi, O. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4592-4597.
21. Suzuki, T.; Ando, T.; Tsuchiya, K.; Nakanishi, O.; Saito, A.; Yamashita, T.; Shiraishi, Y.; Tanaka, E. EP Patent 0 847 992 A1, 1998.
22. (a) Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavietich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
23. Pavietich, N. P.; Finnin, M. S.; Donigian, J. R.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R. US Patent 0024700, 2000.
24. (a) Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S. H.; Abou Khalil, E.; Leit, S.; Fournel, M.; Yan, P. T.; Trachy-Bourget, M. C.; Beaulieu, C.; Li, Z.; Besterman, J.; Delorme, D. Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 2847-2850.
25. Delorme, D.; Ruel, R.; Lavoie, R.; Thibault, C.; Abou-Khalil, E. Inhibitors of histone deacetylase. WO Patent 01/38322 A1, 2001. Chem. Abstr. 2001, 135, 5455.
26. (a) Pikul, S.; Ohler, N. E.; Ciszewski, G.; Laufersweiler, M. C.; Almstead, N. G.; De, B.; Natchus, M. G.; Hsieh, L. C.; Janusz, M. J.; Peng, S. X.; Branch, T. M.; King, S, L.; Taiwo, Y. O.; Mieling G. E. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J. Med. Chem. 2001, 44, 2499-2502.
27. Michaelides, M. R.; Dellaria, J. F.; Gong, J.; Holms, J. H.; Bouska, J. J., Stacey, J.; Wada, C. K.; Heyman, R.; Curtin, M. L.; Guo, Y.; Goodfellow, C. L.; Elmore, I. B.; Albert, D. H.; Magoc, T. J.; Marcotte, P. A.; Morgan, D. W.; Davidsen S. K. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1553-1556.
28. Carmen, A. A.; Rundlett, S. E.; Grunstein, M. HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex. J. Biol. Chem. 1996, 271, 15837-15844.
29. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 10014-10019.
30. (a) Sowa, Y.; Orita, T.; Minamikawa-Hiranabe, S.; Mizuno, T.; Nomura, H.; Sakai, T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. Cancer Res. 1999, 59, 4266-4270.
31. Sandor, V.; Senderowicz, A.; Mertins, S.; Sackett, D.; Sausville, E.; Blagosklonny, M. V.; Bates, S. E. P21-dependent g(1) arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer 2000, 83, 817-825.
32. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Antrapyrazoles, a new class of intercalating agents with high level, broad spectrum activity against murin tumors. Cancer Res. 1985, 45, 5532-5539.